AU2008338204B2 - Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer - Google Patents

Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer Download PDF

Info

Publication number
AU2008338204B2
AU2008338204B2 AU2008338204A AU2008338204A AU2008338204B2 AU 2008338204 B2 AU2008338204 B2 AU 2008338204B2 AU 2008338204 A AU2008338204 A AU 2008338204A AU 2008338204 A AU2008338204 A AU 2008338204A AU 2008338204 B2 AU2008338204 B2 AU 2008338204B2
Authority
AU
Australia
Prior art keywords
gemcitabine
formula
counterion
compound
pancreatic cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008338204A
Other languages
English (en)
Other versions
AU2008338204A1 (en
Inventor
Lyne Gagnon
Lilianne Geerts
Christopher Penney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liminal Biosciences Ltd
Original Assignee
Prometic Pharma SMT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma SMT Ltd filed Critical Prometic Pharma SMT Ltd
Publication of AU2008338204A1 publication Critical patent/AU2008338204A1/en
Application granted granted Critical
Publication of AU2008338204B2 publication Critical patent/AU2008338204B2/en
Assigned to PROMETIC PHARMA SMT LIMITED reassignment PROMETIC PHARMA SMT LIMITED Request for Assignment Assignors: PROMETIC BIOSCIENCES INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008338204A 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer Ceased AU2008338204B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US812907P 2007-12-19 2007-12-19
US61/008,129 2007-12-19
PCT/CA2008/002190 WO2009076761A1 (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Publications (2)

Publication Number Publication Date
AU2008338204A1 AU2008338204A1 (en) 2009-06-25
AU2008338204B2 true AU2008338204B2 (en) 2015-03-05

Family

ID=40795145

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008338204A Ceased AU2008338204B2 (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Country Status (15)

Country Link
US (1) US8946190B2 (enExample)
EP (1) EP2231166B1 (enExample)
JP (1) JP5473937B2 (enExample)
KR (1) KR101603351B1 (enExample)
CN (1) CN101903028B (enExample)
AU (1) AU2008338204B2 (enExample)
BR (1) BRPI0821395A2 (enExample)
CA (1) CA2708679C (enExample)
DK (1) DK2231166T3 (enExample)
ES (1) ES2414617T3 (enExample)
MX (1) MX2010006867A (enExample)
NZ (1) NZ586249A (enExample)
PT (1) PT2231166E (enExample)
TW (1) TWI448290B (enExample)
WO (1) WO2009076761A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011757A (es) 2009-05-04 2012-01-25 Prometic Biosciences Inc Compuestos aromaticos substituidos y usos farmaceuticos.
EA035494B1 (ru) * 2010-10-27 2020-06-25 Прометик Фарма Смт Лимитед Способ и применение композиции для ингибирования миграции клеток опухоли и образования метастазов
CN102617679B (zh) * 2012-03-13 2014-11-26 北京大学 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
EP2956121B1 (en) * 2013-02-12 2018-05-30 Bend Research, Inc. Solid dispersions of low-water solubility actives
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
AU2014222389B2 (en) * 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
US10463684B2 (en) 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
MX2021003750A (es) 2018-10-11 2021-06-15 Basf As Compuestos aromaticos y usos farmaceuticos de los mismos.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083120A2 (en) * 2001-04-18 2002-10-24 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20030049302A1 (en) * 2001-08-29 2003-03-13 Pauletti Giovanni M. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
WO2004069237A1 (en) * 2003-02-07 2004-08-19 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68928756T2 (de) * 1989-03-13 1999-03-04 Cellegy Pharma Inc Topische Zubereitungen enthaltend aliphatische Amine zur Behandlung von Hautkrankheiten
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
US20060012880A1 (en) * 2002-05-02 2006-01-19 Law Benjamin P Optical device with refractive and diffractive properties
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083120A2 (en) * 2001-04-18 2002-10-24 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20030049302A1 (en) * 2001-08-29 2003-03-13 Pauletti Giovanni M. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
WO2004069237A1 (en) * 2003-02-07 2004-08-19 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOORE , M. J. et al., Journal of Clinical Oncology, April 2007, vol. 25, no. 15, pp.1960-1966 *
NKONDJOCK, A. et al., , British Journal of Cancer, 2005, vol. 92, pp.971-977 *

Also Published As

Publication number Publication date
JP5473937B2 (ja) 2014-04-16
NZ586249A (en) 2012-05-25
PT2231166E (pt) 2013-06-17
EP2231166B1 (en) 2013-03-20
EP2231166A4 (en) 2012-02-22
HK1151244A1 (en) 2012-01-27
US20100273731A1 (en) 2010-10-28
EP2231166A1 (en) 2010-09-29
CA2708679C (en) 2016-11-15
KR101603351B1 (ko) 2016-03-14
ES2414617T3 (es) 2013-07-22
CN101903028A (zh) 2010-12-01
BRPI0821395A2 (pt) 2015-06-16
TWI448290B (zh) 2014-08-11
DK2231166T3 (da) 2013-06-24
KR20100101134A (ko) 2010-09-16
US8946190B2 (en) 2015-02-03
CN101903028B (zh) 2013-06-05
JP2011506492A (ja) 2011-03-03
MX2010006867A (es) 2010-08-31
TW200934494A (en) 2009-08-16
WO2009076761A1 (en) 2009-06-25
CA2708679A1 (en) 2009-06-25
AU2008338204A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
CA2708679C (en) Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
US20250120926A1 (en) Pharmaceutical Composition for Preventing or Treating Cancer, Comprising Gossypol, Phenformin, and Anticancer Agent
CN105283180A (zh) Pi3k抑制剂与微管去稳定剂的药物组合
WO2022225045A1 (ja) グレリン抵抗性を伴う悪液質の治療剤又は予防剤
WO2012075754A1 (zh) 一种治疗急性淋巴白血病的复方药物组合物
CN111514140B (zh) 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途
US7863255B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
CN113350325B (zh) 二蒽酮类化合物在制备抗肿瘤药物中的应用
CN115135326B (zh) 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
HK1151244B (en) Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
CN116115623A (zh) 2'-岩藻糖基乳糖作为一种抗肿瘤辅助药物的应用
CN109045052B (zh) 用于治疗结肠癌的药物配方与应用
EP4282408A1 (en) Method for pretreating relapsing cancer
JP7450037B2 (ja) 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品
US20240390352A1 (en) Pharmaceutical composition for preventing or treating cancer comprising carnitine acylcarnitine carrier inhibitor and antitumor agent
WO2005046665A1 (en) Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
CN110876803B (zh) 一种包含乳蛋白和油酸的药物组合物
KR102714321B1 (ko) 대사항암제를 포함하는 항암용 조성물
CN113244242A (zh) 甘草次酸、甘草酸在预防或治疗肺炎/肺纤维化中的应用
KR20230043063A (ko) 카르니틴 아실카르니틴 운반자 억제제 및 카르니틴 옥타노일트랜스퍼라제 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2008064596A1 (fr) Composition pharmaceutique comprenant la protéine p43 pour le traitement de l'adénocarcinome gastrique
JP2004514683A (ja) レバミゾール及び５−フルオロウラシルの同時投与法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PROMETIC PHARMA SMT LIMITED

Free format text: FORMER OWNER WAS: PROMETIC BIOSCIENCES INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired